知镜 Cognispect · 医学文献与研究工作台

Co-existent autoimmune diseases in people with multiple sclerosis and a review on choice of immunotherapy.

Netterwala A, Garg S, Majumdar P, Bhardwaj S, Kumar S, Javali M, Murgod U, Bannerjee TK, Kamath V, Krishnan P, Iyer RB, Badachi S, Shivde S, Huddar A, Sarma GRK, Nadig R, Mathew T.
Immunotherapy · 2026-11-09 · PMID 43001488

文献摘要

Aims Coexisting autoimmune diseases in multiple sclerosis (MS) may influence disease-modifying therapy (DMT) choice, but Indian data remains limited. This study aims to determine the prevalence of co-existent autoimmune disorders in Indian MS patients and assess their impact on DMT selection. Material and methods This multicentre, cross-sectional observational study included 355 adults with MS evaluated across five Indian neuroimmunology clinics between 2016 and 2026. Comorbidity prevalence was compared against general-population estimates, and DMT utilization was compared between patients with and without autoimmune comorbidities. Results Fifty-nine patients (16.6%) had an autoimmune disorder, with hypothyroidism (5.9%), rheumatoid arthritis (RA; 2.0%), and type 1 diabetes mellitus (1.4%) being the most common. Prevalences of RA (2.0% vs 0.49%; p = 0.002) and inflammatory bowel disease (IBD; 0.8% vs 0.02%; p p = 0.003); dimethyl fumarate (22.0% vs 1.4%; p p = 0.004) were prescribed more frequently. Conclusions Autoimmune comorbidity occurred in about 1/6 Indian MS patients, with excess RA and IBD relative to population prevalence and an associated shift in DMT selection.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。